相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Pembrolizumab versus paclitaxel for previously treated PD-L1-positive advanced gastric or gastroesophageal junction cancer: 2-year update of the randomized phase 3 KEYNOTE-061 trial
Charles S. Fuchs et al.
GASTRIC CANCER (2022)
The current and future incidence and mortality of gastric cancer in 185 countries, 2020-40: A population-based modelling study
Eileen Morgan et al.
ECLINICALMEDICINE (2022)
Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Hyuna Sung et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial
Yelena Y. Janjigian et al.
LANCET (2021)
The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2021
Feng-Hua Wang et al.
CANCER COMMUNICATIONS (2021)
The association of molecular biomarkers with efficacy of pembrolizumab versus paclitaxel in patients with gastric cancer (GC) from KEYNOTE-061.
Charles S. Fuchs et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Second-line treatment in advanced gastric cancer: Data from the Spanish AGAMENON registry
Almudena Cotes Sanchis et al.
PLOS ONE (2020)
Efficacy and safety of pembrolizumab (pembro) alone or in combination with chemotherapy (chemo) in patients (pts) with advanced gastric or gastroesophageal (G/GEJ) cancer: Long-term follow up from KEYNOTE-059.
Zev A. Wainberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Docetaxel plus cisplatin and S-1 versus cisplatin and S-1 in patients with advanced gastric cancer (JCOG1013): an open-label, phase 3, randomised controlled trial
Yasuhide Yamada et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2019)
First-line systemic therapy for advanced gastric cancer: a systematic review and network meta-analysis
Ji Cheng et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2019)
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial
Kohei Shitara et al.
LANCET (2018)
Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer Phase 2 Clinical KEYNOTE-059 Trial
Charles S. Fuchs et al.
JAMA ONCOLOGY (2018)
Examining the gastric cancer survival gap between Asians and whites in the United States
Hongbin Jin et al.
GASTRIC CANCER (2017)
Survival after failure of first-line chemotherapy in advanced gastric cancer patients: differences between Japan and the rest of the world
Atsuo Takashima et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2017)
Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial
Kei Muro et al.
LANCET ONCOLOGY (2016)
Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial
Hansjochen Wilke et al.
LANCET ONCOLOGY (2014)